NEW HONEST AND TRUSTWORTHY
氯化钠注射液(软包双硬管)
  • 氯化钠注射液(软包双硬管)
ENGLISH NAME: Sodium  Chloride  Injection 
SPECIFICATIONS: (1) 50 ml : 0.45 g; (2) 100 ml : 0.9 g; (3) 250 ml : 2.25 g; (4) 500 ml : 4.5 g; (5) 1000 ml : 9 g
PRODUCT PACKAGING:  Glass Bottle, Non-PVC Multilayer Co-extrusion Film Infusion Bag, Aseptic Double Chamber Valves, Vertical Polypropylene Infusion Bag, Polypropylene Blending Infusion Bag
FORMULATION: Large Volume Parenteral
STORAGE CONDITION: Shading, Closed, Preservation of the Shade
SHELF LIFE: 24 Months
Previous:Without
Next:Glucose Injection
Description: Each 100 mL of 0.9% Sodium Chloride Injection USP contains:

Sodium Chloride USP 0.9 g; Water for Injection USP qs

pH: 5.6 (4.5-7.0)

Calculated Osmolarity: 308 mOsmol/liter

pH adjusted with Hydrochloric Acid NF

Concentration of Electrolytes (mEq/liter):  Sodium 154       Chloride 154

Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.

The formula of the active ingredient is:

Ingredient   Molecular Formula  Molecular Weight
 Sodium Chloride USP  NaCI  58.44

Pharmacological effects:Sodium Chloride Injection USP provides electrolytes and is a source of water for hydration. It is capable of inducing diuresis depending on the clinical condition of the patient.Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.

Indications:This intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration.0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion.0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells.Sodium Chloride Injection USP is also indicated as a pharmaceutic aid and diluent for the infusion of compatible drug additives. Refer to prescribing information accompanying additive drugs.

Precautions: This solution should be used with care in patients with hypervolemia, renal insufficiency, urinary tract obstruction, or impending or frank cardiac decompensation.Extraordinary electrolyte losses such as may occur during protracted nasogastric suction, vomiting, diarrhea or gastrointestinal fistula drainage may necessitate additional electrolyte supplementation. Additional essential electrolytes, minerals and vitamins should be supplied as needed.Sodium-containing solutions should be administered with caution to patients receiving corticosteroids or corticotropin, or to other salt-retaining patients. Care should be exercised in administering solutions containing sodium to patients with renal or cardiovascular insufficiency, with or without congestive heart failure, particularly if they are postoperative or elderly.
Infusion of more than one liter of isotonic (0.9%) sodium chloride per day may supply more sodium and chloride than normally found in serum, and can exceed normal tolerance, resulting in hypernatremia; this may also cause a loss of bicarbonate ions, resulting in an acidifying effect.To minimize the risk of possible incompatibilities arising from mixing this solution with other additives that may be prescribed, the final infusate should be inspected for cloudiness or precipitation immediately after mixing, prior to administration and periodically during administration.Do not use plastic container in series connection.If administration is controlled by a pumping device, care must be taken to discontinue pumping action before the container runs dry or air embolism may result.This solution is intended for intravenous administration using sterile equipment. It is recommended that intravenous administration apparatus be replaced at least once every 24 hours.Use only if solution is clear and container and seals are intact.Pregnancy Category C. Animal reproduction studies have not been conducted with Sodium Chloride Injection USP. It is also not known whether Sodium Chloride Injection USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection USP should be given to a pregnant woman only if clearly needed.It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Sodium Chloride Injection USP is administered to a nursing woman.Safety and effectiveness of Sodium Chloride Injections in pediatric patients have not been established by adequate and well controlled trials, however, the use of electrolyte solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population.This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Adverse reaction:Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. Hypernatremia may be associated with edema and exacerbation of congestive heart failure due to the retention of water, resulting in an expanded extracellular fluid volume.If infused in large amounts, chloride ions may cause a loss of bicarbonate ions, resulting in an acidifying effect.
Copyright2015 Cisen Pharmaceutical Co., Ltd. All rights reserved. 鲁ICP备14017151号   SP Design